Business
Canadian Clinical Study Sites Re-Commence Bladder Cancer Study
TORONTO, ON / ACCESSWIRE / August 12, 2020 / Theralase ® Technologies Inc. (" Theralas...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Canadian Clinical Study Sites Re-Commence Bladder Cancer StudyTORONTO, ON / ACCESSWIRE / August 12, 2020 / Theralase® Technologies Inc. (\"Theralase\" or \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDC\") and associated drug formulations, announced today that three out of four of its Canadian clinical study sites have re-commenced new patient enrollment and treatment in the Company's Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study (\"Study II\").Specifically:Study SiteLocationSite StatusUniversity Health Network (\"UHN\")Toronto, OntarioEnrollingLondon Health Sciences Centre (\"LHSC\"),London, OntarioEnrollingNova Scotia Health Authority (\"NSHA\")Halifax, Nova ScotiaEnrollingMcGill University Health Centre (\"MUHC\")Montreal, QuebecCOVID-19 HoldOn a go forward basis, all future and existing patients to be enrolled and treated (initial and second treatment) in Study II will be treated using the Study II treatment optimizations as communicated via press release on July 30, 2020, specifically:Bladder volume calculationStudy drug volume calculationStudy device volume calculationStudy device treatment timeFour of the patients previously treated are awaiting second treatment subject to the clinical study site operating room availability. One additional patient is undergoing additional assessments prior to proceeding to second treatment.The Company is in advanced discussions to launch a number of US based clinical study sites, subject to the United States economy recovering from the COVID-19 pandemic.The US based Trial Management Organization (\"TMO\") could potentially launch 4 clinical study sites in 4Q2020 and commence Study II patient enrollment and treatment in 1Q2021.Shawn Shirazi, Ph.D., Chief Executive Officer of Theralase stated, \"Theralase is pleased that 3 out of 4 Canadian clinical study sites are open for new patient enrollment and treatment receiving the new optimized Study II treatment. The clinical data collected on the first twelve patients treated shows a favorable clinical response, which the Company expects will improve due to the implemented Study II treatment optimization.\"About Study IIStudy II utilizes the Therapeutic Dose (0.70 mg/cm2) of TLD-1433 and is focuse...